Elder pharma aims Rs 100 crore from global sales of Shelcal by FY18

15 Jun 2015 Evaluate

In a view of increasing exports base to Europe, Asia and African countries, Elder pharmaceuticals is aiming to garner Rs 100 crore from global sales of its calcium supplement brand Shelcal by 2017-18. The company had sold Shelcal’s domestic market rights and 30 other brands to Torrent group last year for Rs 2,000 crore but had retained the rights for the international markets.

The company is also looking to export another nutritional product,Thrive, a natural supplement that helps fight chronic metabolic disorders. It is looking at strong prescription base in over 70 countries by March 2017.

Elder Pharmaceuticals has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.

 

 

Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×